Ironwood Pharmaceuticals Inc (IRWD) reports robust LINZESS sales growth and outlines strategic plans for increased revenue and debt reduction in 2026.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...

Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. Click ...

Q4 2025 net price was negatively impacted by the timing of gross-to-net rebate reserves where units dispensed exceeded units sold to wholesalers. Management expects a more than 30% increase in ...

Lindsey DeSoto, RD, is a nutrition writer, medical reviewer, and registered dietitian who helps clients improve their diet for health-related reasons. Her writing covers a variety of topics, including ...